Difference between revisions of "Binimetinib (Mektovi)"
Jump to navigation
Jump to search
m (→Also known as) |
m |
||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=653635 NCI Drug Dictionary]: An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. | From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=653635 NCI Drug Dictionary]: An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. | ||
| − | =Diseases for which it is used= | + | ==Diseases for which it is used== |
*[[Melanoma,_BRAF-mutated|BRAF-mutant melanoma]] | *[[Melanoma,_BRAF-mutated|BRAF-mutant melanoma]] | ||
*[[Melanoma,_NRAS-mutated|NRAS-mutant melanoma]] | *[[Melanoma,_NRAS-mutated|NRAS-mutant melanoma]] | ||
| − | =History of changes in FDA indication= | + | ==History of changes in FDA indication== |
| − | *6/27/2018: Initial FDA approval in combination with [[Encorafenib (Braftovi)]] | + | *6/27/2018: Initial FDA approval in combination with [[Encorafenib (Braftovi)]] for patients with unresectable or metastatic [[melanoma]] with a [[Biomarkers#BRAF|BRAF]] [[Biomarkers#V600E|V600E]] or [[Biomarkers#V600K|V600K mutation]], as detected by an FDA-approved test. |
| − | =Also known as= | + | ==Also known as== |
*'''Code names:''' ARRY-162, ARRY-438162, MEK162 | *'''Code names:''' ARRY-162, ARRY-438162, MEK162 | ||
| − | *'''Brand | + | *'''Brand names:''' Braftovi, Mektovi |
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| + | [[Category:Mutation-specific medications]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
Revision as of 21:26, 11 January 2020
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2.
Diseases for which it is used
History of changes in FDA indication
- 6/27/2018: Initial FDA approval in combination with Encorafenib (Braftovi) for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Also known as
- Code names: ARRY-162, ARRY-438162, MEK162
- Brand names: Braftovi, Mektovi